LFST

Over the past six months, LifeStance's stock was impacted by strong earnings reports and raised guidance in Q1 and Q2 2026, exceeding analyst expectations. Secondary offerings by selling stockholders occurred in May and September 2026, with the company repurchasing a portion of shares. Analyst optimism from firms like KeyBanc and Canaccord in October 2026 led to raised price targets. There was notable insider selling, including TPG GP A and the CTO trimming stakes, while institutional ownership increased, with BlackRock, Inc. disclosing a 10.1% passive stake. The stock experienced a significant rally of approximately 87-90%, though broader market weakness in September 2026 negatively impacted the healthcare sector, including LFST.